Varicella zoster virus

Varicella zoster virus
Photo Credit: Content Providers(s): CDC/Dr. Erskine Palmer/B.G. Partin · Public domain · source
Name	Varicella zoster virus
Virus group	DNA virus (Herpesviridae)
Family	Herpesviridae
Genus	Varicellovirus
Species	Varicella zoster virus

Varicella zoster virus is a human alpha‑herpesvirus that causes primary varicella (chickenpox) and reactivation disease herpes zoster (shingles). It is an enveloped, double‑stranded DNA virus associated with substantial clinical, public health, and research interest across institutions such as the Centers for Disease Control and Prevention, World Health Organization, and major academic centers including Johns Hopkins University, Harvard University, and Stanford University. Control strategies link vaccine programs led by manufacturers like Merck & Co. and regulatory decisions from agencies such as the Food and Drug Administration and European Medicines Agency.

Virology

The virus belongs to the family Herpesviridae and genus Varicellovirus, sharing structural features with other alphaherpesviruses such as Herpes simplex virus 1, Herpes simplex virus 2, and Pseudorabies virus. Its linear double‑stranded DNA genome encodes approximately 70 open reading frames analogous to those characterized in comparisons with Epstein–Barr virus and Cytomegalovirus. The virion architecture comprises an icosahedral capsid enveloped by a lipid bilayer containing glycoproteins homologous to those studied in Vaccinia virus research. Genome sequencing initiatives at institutions like the National Institutes of Health and projects funded by the Wellcome Trust have elucidated strain variation and phylogenetic relationships relevant to transmission studies conducted in settings including Centers for Disease Control and Prevention headquarters and university virology labs at University of Oxford and University of Cambridge.

Pathogenesis and Life Cycle

Primary infection typically begins in the respiratory mucosa with cell entry mediated by interactions between viral glycoproteins and host receptors, a mechanism explored in molecular studies at Massachusetts Institute of Technology and California Institute of Technology. Following replication in epithelial cells, the virus disseminates via viremia to skin, where the characteristic vesicular rash develops; these processes were delineated in pathogenesis work from Rockefeller University and Yale University. Latency is established in sensory ganglia such as dorsal root ganglia and trigeminal ganglia, paralleling latency phenomena described for Rabies virus and investigated with techniques from the Sanger Centre and Broad Institute. Reactivation, producing herpes zoster, is influenced by immunosenescence and immunosuppression studied in cohorts at Mayo Clinic and Cleveland Clinic, as well as within clinical trials coordinated by World Health Organization collaborating centers.

Clinical Manifestations

Primary varicella presents with fever and a generalized pruritic vesicular rash, clinical patterns compared historically to rash descriptions in texts from Guy's Hospital and case series in journals associated with The Lancet and New England Journal of Medicine. Complications include secondary bacterial infection, varicella pneumonia, and neurological syndromes such as encephalitis and cerebellitis; such complications have been reported in clinical reports from King's College Hospital and Mayo Clinic case registries. Herpes zoster manifests as a painful, dermatomal vesicular eruption and can lead to postherpetic neuralgia, studied in pain clinics at Johns Hopkins Hospital and University College London Hospitals. Ophthalmic zoster involving the trigeminal distribution is managed in specialist centers including Bascom Palmer Eye Institute and has been documented in cohorts described in publications from American Academy of Ophthalmology meetings.

Diagnosis

Diagnosis integrates clinical assessment with laboratory confirmation using polymerase chain reaction assays developed at laboratories such as Centers for Disease Control and Prevention and commercial diagnostics from firms like Roche and Abbott Laboratories. Serologic testing for varicella‑specific IgM and IgG informs susceptibility assessment in populations managed by Occupational Safety and Health Administration guidelines and pre‑exposure screening in healthcare workers at facilities like Mount Sinai Hospital. Direct detection methods, including viral culture and immunofluorescence, were refined in virology units at Nuffield Department of Medicine and national reference laboratories coordinated by Public Health England and equivalents.

Prevention and Treatment

Live attenuated varicella vaccines developed by manufacturers including Merck & Co. and immunization policies from agencies such as the Advisory Committee on Immunization Practices have dramatically reduced incidence in countries implementing routine childhood immunization programs endorsed by the World Health Organization. A recombinant zoster vaccine developed and licensed following clinical trials led by research centers at University of California, San Diego and University of Texas MD Anderson Cancer Center provides high protection against herpes zoster in older adults. Antiviral therapies such as acyclovir, valacyclovir, and famciclovir—initially characterized in pharmacology research at GlaxoSmithKline and Roche—are standard treatments for acute infection and prophylaxis in immunocompromised patients treated at centers like Dana‑Farber Cancer Institute. Public health interventions have been shaped by immunization campaigns coordinated by Centers for Disease Control and Prevention and vaccination mandates in educational institutions like University of Michigan and school systems across United Kingdom and United States.

Epidemiology

Historically endemic with seasonal peaks, varicella incidence patterns vary by region with surveillance data collected by World Health Organization and national bodies such as Public Health England and the Centers for Disease Control and Prevention. Introduction of childhood vaccination programs in countries like United States, Australia, and Japan produced marked declines in case counts and hospitalizations reported by National Health Service (England) and national health agencies. Herd immunity thresholds, outbreak investigations, and modeling studies have been conducted by teams at Imperial College London, London School of Hygiene & Tropical Medicine, and Johns Hopkins Bloomberg School of Public Health to inform policy decisions on vaccine schedules and booster recommendations.

History and Research Developments

Clinical descriptions of chickenpox date to classical medical writings and were refined during epidemiologic work in the 19th and 20th centuries at institutions such as Guy's Hospital and St Bartholomew's Hospital. The viral etiology was established with virology breakthroughs at Rockefeller University and subsequent culturing techniques developed at Pasteur Institute. Vaccine development milestones include the licensure of live attenuated vaccine by Merck & Co. and later recombinant vaccine approvals guided by regulatory reviews at the Food and Drug Administration and European Medicines Agency. Recent research frontiers—investigating viral latency, immune correlates of protection, and antiviral resistance—are active at research centers including the Broad Institute, Sanger Institute, Fred Hutchinson Cancer Research Center, and universities such as Harvard Medical School and University of California, San Francisco.

Category:Herpesviridae